journal
MENU ▼
Read by QxMD icon Read
search

Nature Reviews. Clinical Oncology

journal
https://www.readbyqxmd.com/read/28322244/targeted-therapies-new-standard-for-relapsed-all
#1
Lisa Hutchinson
No abstract text is available yet for this article.
March 21, 2017: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/28322243/immunotherapy-genomic-and-immunological-features-predict-a-response
#2
Peter Sidaway
No abstract text is available yet for this article.
March 21, 2017: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/28290493/pancreatic-cancer-new-biomarkers-improve-standard-screening
#3
Peter Sidaway
No abstract text is available yet for this article.
March 14, 2017: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/28290492/haematological-cancer-treg-predict-responsiveness-to-blinatumomab
#4
Peter Sidaway
No abstract text is available yet for this article.
March 14, 2017: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/28290491/ovarian-cancer-algorithm-enables-early-detection
#5
Peter Sidaway
No abstract text is available yet for this article.
March 14, 2017: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/28290490/the-high-price-of-anticancer-drugs-origins-implications-barriers-solutions
#6
REVIEW
Vinay Prasad, Kevin De Jesús, Sham Mailankody
Globally, annual spending on anticancer drugs is around US$100 billion, and is predicted to rise to $150 billion by 2020. In the USA, a novel anticancer drug routinely costs more than $100,000 per year of treatment. When adjusted for per capita spending power, however, drugs are most unaffordable in economically developing nations, such as India and China. Not only are launch prices high and rising, but individual drug prices are often escalated during exclusivity periods. High drug prices harm patients - often directly through increased out-of-pocket expenses, which reduce levels of patient compliance and lead to unfavourable outcomes - and harms society - by imposing cumulative price burdens that are unsustainable...
March 14, 2017: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/28290489/charged-particle-therapy-in-cancer-clinical-uses-and-future-perspectives
#7
REVIEW
Marco Durante, Roberto Orecchia, Jay S Loeffler
Radiotherapy with high-energy charged particles has become an attractive therapeutic option for patients with several tumour types because this approach better spares healthy tissue from radiation than conventional photon therapy. The cost associated with the delivery of charged particles, however, is higher than that of even the most elaborate photon-delivery technologies. Reliable evidence of the relative cost-effectiveness of both modalities can only come from the results of randomized clinical trials. Thus, the hurdles that currently limit direct comparisons of these two approaches in clinical trials, especially those related to insurance coverage, should be removed...
March 14, 2017: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/28290488/colorectal-cancer-screening-provides-long-term-benefits
#8
Peter Sidaway
No abstract text is available yet for this article.
March 14, 2017: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/28266521/genetics-fitness-depends-on-kras-imbalance
#9
Diana Romero
No abstract text is available yet for this article.
March 7, 2017: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/28266520/targeted-therapies-reversal-of-fortunes-for-tki-resistance
#10
Louise Stone
No abstract text is available yet for this article.
March 7, 2017: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/28252003/integrating-liquid-biopsies-into-the-management-of-cancer
#11
REVIEW
Giulia Siravegna, Silvia Marsoni, Salvatore Siena, Alberto Bardelli
During cancer progression and treatment, multiple subclonal populations of tumour cells compete with one another, with selective pressures leading to the emergence of predominant subclones that replicate and spread most proficiently, and are least susceptible to treatment. At present, the molecular landscapes of solid tumours are established using surgical or biopsy tissue samples. Tissue-based tumour profiles are, however, subject to sampling bias, provide only a snapshot of tumour heterogeneity, and cannot be obtained repeatedly...
March 2, 2017: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/28195238/the-changing-landscape-of-clinical-trial-and-approval-processes-in-china
#12
REVIEW
Qing Zhou, Xiao-Yuan Chen, Zhi-Min Yang, Yi-Long Wu
In the past decade, the standards of clinical trials in China have moved closer to international standards, thus encouraging the development of innovative drugs. However, a large backlog of pending applications for both drug approval and clinical trial registration has arisen owing to the complexity of the approval process, the volume of applications and a lack of staff available to process these applications, among other reasons. To improve the drug approval process, a 'four-colour-light' strategy was introduced...
February 14, 2017: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/28169302/precision-medicine-needs-randomized-clinical-trials
#13
REVIEW
Everardo D Saad, Xavier Paoletti, Tomasz Burzykowski, Marc Buyse
The advent of precision medicine has prompted profound changes in clinical cancer research, and the rising numbers of new therapeutic agents pose challenges in terms of the most appropriate trial designs and effects on the drug-approval process. In the past 5 years, some remarkably efficacious drugs have been approved based on evidence from uncontrolled phase I trials. We challenge the view that the expected benefits from new drugs are generally sufficient to forgo a randomized trial with patients assigned to a control arm (a regimen other than the experimental treatment)...
February 7, 2017: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/28117417/proteasome-inhibitors-in-cancer-therapy
#14
REVIEW
Elisabet E Manasanch, Robert Z Orlowski
The ubiquitin proteasome pathway was discovered in the 1980s to be a central component of the cellular protein-degradation machinery with essential functions in homeostasis, which include preventing the accumulation of misfolded or deleterious proteins. Cancer cells produce proteins that promote both cell survival and proliferation, and/or inhibit mechanisms of cell death. This notion set the stage for preclinical testing of proteasome inhibitors as a means to shift this fine equilibrium towards cell death...
January 24, 2017: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/28117416/tumour-associated-macrophages-as-treatment-targets-in-oncology
#15
REVIEW
Alberto Mantovani, Federica Marchesi, Alberto Malesci, Luigi Laghi, Paola Allavena
Macrophages are crucial drivers of tumour-promoting inflammation. Tumour-associated macrophages (TAMs) contribute to tumour progression at different levels: by promoting genetic instability, nurturing cancer stem cells, supporting metastasis, and taming protective adaptive immunity. TAMs can exert a dual, yin-yang influence on the effectiveness of cytoreductive therapies (chemotherapy and radiotherapy), either antagonizing the antitumour activity of these treatments by orchestrating a tumour-promoting, tissue-repair response or, instead, enhancing the overall antineoplastic effect...
January 24, 2017: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/28094266/cancer-metabolism-a-therapeutic-perspective
#16
Ubaldo E Martinez-Outschoorn, Maria Peiris-Pagés, Richard G Pestell, Federica Sotgia, Michael P Lisanti
No abstract text is available yet for this article.
January 17, 2017: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/28094262/radiotherapy-and-immunotherapy-a-beneficial-liaison
#17
REVIEW
Ralph R Weichselbaum, Hua Liang, Liufu Deng, Yang-Xin Fu
Investigations into the interaction between radiotherapy and the host immune system have uncovered new mechanisms that can potentially be exploited to improve the efficacy of radiotherapy. Radiation promotes the release of danger signals and chemokines that recruit inflammatory cells into the tumour microenvironment, including antigen-presenting cells that activate cytotoxic T-cell function. By contrast, radiation can attract immunosuppressive cells into the tumour microenvironment. In rare circumstances, the antitumour effect of radiotherapy has been observed outside of the radiation field, known as the abscopal effect...
January 17, 2017: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/28094261/beyond-the-margins-real-time-detection-of-cancer-using-targeted-fluorophores
#18
REVIEW
Ray R Zhang, Alexandra B Schroeder, Joseph J Grudzinski, Eben L Rosenthal, Jason M Warram, Anatoly N Pinchuk, Kevin W Eliceiri, John S Kuo, Jamey P Weichert
Over the past two decades, synergistic innovations in imaging technology have resulted in a revolution in which a range of biomedical applications are now benefiting from fluorescence imaging. Specifically, advances in fluorophore chemistry and imaging hardware, and the identification of targetable biomarkers have now positioned intraoperative fluorescence as a highly specific real-time detection modality for surgeons in oncology. In particular, the deeper tissue penetration and limited autofluorescence of near-infrared (NIR) fluorescence imaging improves the translational potential of this modality over visible-light fluorescence imaging...
January 17, 2017: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/28031560/the-landscape-of-new-drugs-in-lymphoma
#19
REVIEW
Anas Younes, Stephen Ansell, Nathan Fowler, Wyndham Wilson, Sven de Vos, John Seymour, Ranjana Advani, Andres Forero, Franck Morschhauser, Marie Jose Kersten, Kensei Tobinai, Pier Luigi Zinzani, Emanuele Zucca, Jeremy Abramson, Julie Vose
The landscape of drugs for the treatment of lymphoma has become crowded in light of the plethora of new agents, necessitating the efficient prioritization of drugs for expedited development. The number of drugs available, and the fact that many can be given for an extended period of time, has resulted in the emergence of new challenges; these include determining the optimal duration of therapy, and the need to balance costs, benefits, and the risk of late-onset toxicities. Moreover, with the increase in the number of available investigational drugs, the number of possible combinations is becoming overwhelming, which necessitates prioritization plans for the selective development of novel combination regimens...
December 29, 2016: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/28031557/immunotherapy-benefit-with-anti-pd-l1
#20
Diana Romero
No abstract text is available yet for this article.
December 29, 2016: Nature Reviews. Clinical Oncology
journal
journal
20200
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"